UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 200

Sortiert nach

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

The New England journal of medicine, 2016-07, Vol.375 (4), p.345-356

2016

Volltextzugriff (PDF)

Current perspectives of the roles of the central norepinephrine system in anxiety and depression

Depression and anxiety, 2010-04, Vol.27 (4), p.339-350

2010

Volltextzugriff (PDF)

The Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia Areata

Dermatology and therapy, 2023-07, Vol.13 (7), p.1503-1515

2023

Volltextzugriff (PDF)

Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China

Chinese medical journal, 2011-10, Vol.124 (20), p.3260-3268

2011

Volltextzugriff (PDF)

Safety and Tolerability of Atomoxetine Over 3 to 4 Years in Children and Adolescents With ADHD

Journal of the American Academy of Child and Adolescent Psychiatry, 2009-02, Vol.48 (2), p.176-185

2009

Volltextzugriff (PDF)

Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies

Psychotherapy and psychosomatics, 2017-01, Vol.86 (5), p.260-267

2017

Volltextzugriff (PDF)

Validation of the geriatric anxiety inventory in a duloxetine clinical trial for elderly adults with generalized anxiety disorder

International psychogeriatrics, 2015-09, Vol.27 (9), p.1533-1539

2015

Volltextzugriff (PDF)

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary

Drugs in context, 2013-01, Vol.2013, p.212245-212245

2013

Volltextzugriff (PDF)

Ixekizumab for psoriasis – Authors' reply

The Lancet (British edition), 2016-01, Vol.387 (10015), p.226-227

2016

Volltextzugriff (PDF)

Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

Journal of clinical psychopharmacology, 2015-06, Vol.35 (3), p.266-272

2015

Volltextzugriff (PDF)

Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment

The journal of clinical psychiatry, 2016-05, Vol.77 (5), p.635

2016

Volltextzugriff (PDF)

Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double-blind placebo-controlled trial

European neuropsychopharmacology, 2008-09, Vol.18 (9), p.673-681

2008

Volltextzugriff (PDF)

Functional Outcomes in the Treatment of Adults With ADHD

Journal of attention disorders, 2008-05, Vol.11 (6), p.720-727

2008

Volltextzugriff (PDF)

Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline

The journal of clinical psychiatry, 2005-01, Vol.66 (1), p.94

2005

Volltextzugriff (PDF)

Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies

The journal of clinical psychiatry, 2007-04, Vol.68 (4), p.518

2007

Volltextzugriff (PDF)

Duloxetine in the treatment of generalized anxiety disorder

Expert review of neurotherapeutics, 2009-02, Vol.9 (2), p.155-165

2009

Volltextzugriff (PDF)

Fluoxetine and adult suicidality revisited : An updated meta-analysis using expanded data sources from placebo-controlled trials

Journal of clinical psychopharmacology, 2007-12, Vol.27 (6), p.682-686

2007

Volltextzugriff (PDF)

44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB42-AB42

2023

Volltextzugriff (PDF)

Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder

Human psychopharmacology, 2011-04, Vol.26 (3), p.258-266

2011

Volltextzugriff (PDF)

A continuous responder analysis from a long-term trial of duloxetine treatment for generalized anxiety disorder: implications for the randomized withdrawal relapse prevention study design

Journal of clinical psychopharmacology, 2009-02, Vol.29 (1), p.96-97

2009

Volltextzugriff (PDF)

Symptom subtypes of obsessive-compulsive disorder in behavioral treatment studies: a quantitative review

Behaviour research and therapy, 1996, Vol.34 (1), p.47-51

1996

Volltextzugriff (PDF)

Efficacy of duloxetine on painful physical symptoms in major depressive disorder for patients with clinically significant painful physical symptoms at baseline: a meta-analysis of 11 double-blind, placebo-controlled clinical trials

Primary care companion for CNS disorders, 2011, Vol.13 (6)

2011

Volltextzugriff (PDF)

15054 Impact of baricitinib on patient-reported skin symptoms, itch, and quality of life in adult patients with moderate to severe atopic dermatitis and an inadequate response to topical therapies from phase 3 trials BREEZE-AD1 and BREEZE-AD2

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB28-AB28

2020

Volltextzugriff (PDF)

Depression and Generalized Anxiety Symptoms in Panic Disorder Implications for Comorbidity

The journal of nervous and mental disease, 1995-05, Vol.183 (5), p.304-308

1995

Volltextzugriff (PDF)

Predicting Prospective Episodes of Depression in Patients With Panic Disorder: A Longitudinal Study

Journal of consulting and clinical psychology, 1994-04, Vol.62 (2), p.359-365

1994

Volltextzugriff (PDF)

1 – 25 von 200

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(185)
Mit Volltextzugriff
(157)

Publikationsform

Artikel
(197)
Bücher
(3)

Sprache

Englisch
(199)
Japanisch
(23)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Current perspectives of the roles of the central norepinephrine system in anxiety and depression

The Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia Areata

Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China

Safety and Tolerability of Atomoxetine Over 3 to 4 Years in Children and Adolescents With ADHD

Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies

Validation of the geriatric anxiety inventory in a duloxetine clinical trial for elderly adults with generalized anxiety disorder

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary

Ixekizumab for psoriasis – Authors' reply

Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment

Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double-blind placebo-controlled trial

Functional Outcomes in the Treatment of Adults With ADHD

Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline

Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies

Duloxetine in the treatment of generalized anxiety disorder

Fluoxetine and adult suicidality revisited : An updated meta-analysis using expanded data sources from placebo-controlled trials

44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2

Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder

A continuous responder analysis from a long-term trial of duloxetine treatment for generalized anxiety disorder: implications for the randomized withdrawal relapse prevention study design

Symptom subtypes of obsessive-compulsive disorder in behavioral treatment studies: a quantitative review

Efficacy of duloxetine on painful physical symptoms in major depressive disorder for patients with clinically significant painful physical symptoms at baseline: a meta-analysis of 11 double-blind, placebo-controlled clinical trials

15054 Impact of baricitinib on patient-reported skin symptoms, itch, and quality of life in adult patients with moderate to severe atopic dermatitis and an inadequate response to topical therapies from phase 3 trials BREEZE-AD1 and BREEZE-AD2

Depression and Generalized Anxiety Symptoms in Panic Disorder Implications for Comorbidity

Predicting Prospective Episodes of Depression in Patients With Panic Disorder: A Longitudinal Study

Suchergebnisse filtern